-+ 0.00%
-+ 0.00%
-+ 0.00%

Corvus Pharma posts corporate deck highlighting soquelitinib ITK inhibitor program across immune diseases and T‑cell lymphoma

PUBT·06/03/2026 20:24:14
Listen to the news
Corvus Pharma posts corporate deck highlighting soquelitinib ITK inhibitor program across immune diseases and T‑cell lymphoma
  • Corvus highlighted soquelitinib as an oral, highly selective ITK inhibitor positioned as a first-in-class immune modulator across inflammatory diseases.
  • Phase 3 study in peripheral T-cell lymphoma continues to enroll; futility analysis targeted for year-end 2026; program holds orphan drug, fast track designations.
  • In placebo-controlled Phase 1 atopic dermatitis, 200 mg twice daily dosing showed increasing response with longer treatment; Phase 2 is enrolling with data expected mid-2027.
  • Pipeline expansion outlined for asthma, hidradenitis suppurativa; Phase 2 starts planned for 2H 2026.
  • Intellectual property cited as composition-of-matter protection through 2042.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.